Company profile

Ticker
EVFM
Exchange
Website
CEO
Saundra L. Pelletier
Employees
Incorporated in
Location
Fiscal year end
Former names
Neothetics, Inc.
SEC CIK

EVFM stock data

(
)
FINRA relative short interest over last month (20 trading days) ?

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

6 May 20
27 May 20
31 Dec 20

News

Company financial data Financial data

Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Net income -19.15M -12.72M -13.8M -35.45M
Diluted EPS -0.4 -0.27 -0.3 -0.97
Operating income -19.24M -12.87M -14.3M -11.94M
Net change in cash -6.79M -16.55M -18.58M 50.5M
Cash on hand 8.79M 15.57M 32.12M 50.7M
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Net income -80.03M -125.71M -105.31M -13.02M
Diluted EPS -1.99 -5.74 -55.78 -5.66
Operating income -52.74M -77.64M -35.69M -12.04M
Net change in cash 14.24M 119K -10.27M -26.27M
Cash on hand 15.57M 1.33M 1.21M 11.48M

Financial data from company earnings reports

Date Owner Security Transaction Code $Price #Shares $Value #Remaining
22 May 20 Fitzpatrick Alexander A Common Stock Payment of exercise Dispose F 4.99 39,487 197.04K 166,042
22 May 20 Culwell Kelly Common Stock Payment of exercise Dispose F 4.99 39,435 196.78K 146,999
22 May 20 File Justin J. Common Stock Payment of exercise Dispose F 4.99 42,262 210.89K 280,415
22 May 20 Pelletier Saundra L Common Stock Payment of exercise Dispose F 4.99 84,525 421.78K 564,705
22 May 20 Barrans Russell Common Stock Payment of exercise Dispose F 4.99 19,474 97.18K 308,964
13F holders
Current Prev Q Change
Total holders 0 0 NaN%
Opened positions 0 0 NaN%
Closed positions 0 0 NaN%
Increased positions 0 0 NaN%
Reduced positions 0 0 NaN%
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

?
Competition
AllerganAllergan
Risks
  • Our financial condition, clinical development efforts, and results of operations could be adversely affected by the ongoing coronavirus outbreak.
  • Anti-takeover provisions in our stockholder rights plan could make a third-party acquisition of us difficult.
Management Discussion
  • Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
  • You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of this report, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis.
  • We are a San Diego-based clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health. We exist to advance the lives of women by developing innovative solutions, such as woman-controlled contraception and potential protection from certain sexually transmitted infections (STIs). Our lead Multipurpose Vaginal pH Regulator (MVP-RTM) product candidate, Phexxi (L-lactic acid, citric acid, and potassium bitartrate), is in development for multiple potential indications: prevention of pregnancy, prevention of urogenital transmission of Chlamydia trachomatis infection (chlamydia) in women and prevention of urogenital transmission of Neisseria gonorrhoeae infection (gonorrhea) in women.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: accessibility, acquisition, acute, advertising, afflicted, agent, alternate, alternative, altogether, anniversary, ATM, attempt, attention, avoid, Baker, beneficial, beneficially, Black, blocker, buy, call, callable, cGMP, China, clearance, cloud, communication, conditionally, confidence, contact, copy, cyber, delay, delivered, delivery, deploy, discontinue, discouraging, disease, disruption, distancing, diversion, domestic, DPT, duration, economic, encourage, enthusiastic, entry, evolving, expenditure, failure, feet, fleet, FM, focused, foregoing, foreign, forfeited, furlough, globe, good, greater, greatly, highly, holder, home, hospital, important, imposed, inconsistent, inspection, interrupt, interruption, issuable, large, led, Lessee, lessor, linked, local, located, location, lower, lowest, LP, manner, Master, Merton, minimize, mirroring, missed, moved, multiplied, national, Nationally, negotiate, Notwithstanding, null, outbreak, outlook, ownership, pandemic, passed, passing, PDUFA, Phexxi, PhexxiTM, Philadelphia, Piper, power, precautionary, presence, preservation, prioritization, prolonged, prospective, purport, raw, reached, regional, rely, remedy, remotely, rentable, respiratory, rest, Sandler, senior, serialization, shipping, situation, slowdown, small, social, software, spread, square, staffing, strain, successor, surfaced, syndrome, takeover, temporarily, tender, tenure, thereof, threat, Threshold, training, transport, Trust, type, uncertain, unexpected, unexpectedly, unfavorable, unforeseen, unsolicited, void, voided, volume, VWAP, workplace, worsen, Wuhan
Removed: absence, acceleration, achieved, acquiree, acquirer, adjusted, advantage, America, American, applied, applying, approach, approximated, attributable, audit, authorization, awarded, bear, bifurcation, blank, building, BV, campaign, cancel, carefully, Carlo, Certified, Codification, combined, comparative, comply, consisted, contra, CRO, deducting, defer, derivative, detail, differentiate, diminishing, discretionary, dose, Dutch, effected, effecting, EGC, embedded, emerging, ENA, enrolled, envision, EP, EVFM, Evolution, exist, exit, exited, extinguishment, footnote, formulation, fourth, generating, Guide, highest, hindsight, hybrid, identifiable, imputed, inactive, Institute, instrument, invoiced, IPO, iv, judgment, Jumpstart, label, launched, left, legacy, liquidation, LLC, marketability, matured, measure, method, mid, modify, Monte, nature, Network, noncontrolling, North, obligor, officially, opening, overallotment, package, participated, partnership, permitted, Pharma, Practice, preference, PWERM, recapitalization, recasting, reclassified, redeemable, redemption, referenced, registration, reliably, repaid, represented, restatement, resubmit, retained, retrospective, revalued, revised, RSU, sensitive, sensitivity, side, simulation, SPA, split, sponsor, sponsorship, STI, study, successive, symbol, ticker, traded, transferable, transition, treatment, Tryst, twelve, underwriter, underwritten, unexercised, unrelated, valuation, WCGT